How To Invest Like Billionaire Hedge Fund Manager Israel Englander

Israel Englander, a billionaire hedge fund manager, is the Chairman and CEO of Millennium Management. Let's look at some of the recent moves of Catapult Capital Management, a subsidiary of Millennium Management. In the past quarter, Englander's hedge fund made an average return of +8.98 percent on its investments. In the last three years, the fund has an annualized average return of +21.93 percent.

In the most recent quarter, Englander reduced his holdings in Teva Pharmaceutical Industries Ltd (ADR) TEVA by 77.97 percent. Teva is a market leader in several generic pharmaceutical segments. Although the company has a strong balance sheet, it faces strong competition for Copaxone, the company's generic brand. However, Englander's bearish views are different from the 14 analysts who have recently rated the company. According to TipRanks, 13 of the analysts have indicated the stock as a Buy and only 1 has given a Hold rating. In July, Teva's stock had hit a high of $72; yesterday the stock closed at $60.95.

In the semiconductor sector, Englander added NXP Semiconductors NV NXPI to his portfolio. NXP Semi has been in the news in relation to its acquisition of Freescale Semiconductor Ltd.; the company's rival in the US. On September 17, regulators in the European Union approved the acquisition. The combined company created out of this merger will have a market value of over $30 billion. Englander's sentiments on NXP are echoed by all 6 analysts who have recently rated the stock on TipRanks, with all of them giving a Buy rating. Based on the views of the analysts, the average price target for the stock is $127, a 48.23 percent upside from present levels.

Among his other moves, Englander recently added shares of Gilead Sciences, Inc. GILD to his portfolio. The company makes up around 1 percent of his total portfolio, with his stake valued at $7.47 million (as of September 25^th). Since the beginning of 2013, shares of Gilead have increased by nearly 200 percent. On September 21^st, the company had announced a positive update on four Phase 3 clinical studies for treating all six genotypes of chronic Hepatitis C. The company already has a leadership position in the treatment of Hepatitis C, with two of its drugs – Harvoni and Sovaldi– being blockbuster Hep C drugs. All the 12 analysts who have recently rated the stock on TipRanks have given a Buy rating to Gilead, in line with Englander's views.